免疫检查点抑制剂相关风湿与骨骼肌肉免疫不良事件:系统综述
临床试验中关节痛报告率为1-43%,肌痛为2-20%,33项试验中仅5项报告关节炎,2项报告血管炎;现有证据对炎症性关节炎、血管炎、干燥综合征等风湿性IRAEs的患病率尚不明确,且关于既往自身免疫性疾病患者使用ICIs的观察性和病例级证据有限。
要点
- ICIs治疗患者中关节痛和肌痛报告常见,临床试验关节痛患病率范围1-43%,肌痛2-20%。
- 炎症性关节炎、血管炎、干燥综合征等风湿性IRAEs的患病率在现有证据中尚不明确。
- 关于既往自身免疫性疾病患者使用ICIs的证据仅来自1项观察性研究和3例病例报告。
核心结论
- 关节痛和肌痛在ICIs治疗患者中报告常见。
- 炎症性关节炎、血管炎和干燥综合征等风湿性IRAEs的患病率从当前证据中尚不明确。
- 描述既往自身免疫性疾病患者使用ICIs的观察性和病例级证据有限。
研究设计与样本
- 系统综述,检索Medline和CENTRAL数据库中报告ICIs继发风湿与骨骼肌肉IRAEs的文章。
- 双人筛选摘要和全文后提取并总结临床特征、患病率和治疗数据。
- 纳入文献中33项为临床试验,3项为观察性研究,16项为病例报告或系列。
主要发现
- 临床试验中关节痛患病率范围为1-43%,肌痛报告率为2-20%。
- 33项临床试验中5项报告关节炎,仅2项报告血管炎。
- 1项观察性研究和3例病例报告描述了既往自身免疫性疾病患者接受ICIs治疗。
- 病例报告包括发生炎症性关节炎、血管炎、肌炎和狼疮性肾炎。
临床怎么用
- 临床应关注ICIs治疗患者中关节痛和肌痛的报告。
- 对炎症性关节炎、血管炎、干燥综合征等风湿性IRAEs的识别需结合现有有限证据。
- 既往自身免疫性疾病患者使用ICIs的决策应参考有限的观察性和病例级证据。
局限性
- 风湿性IRAEs如炎症性关节炎、血管炎和干燥综合征的患病率从当前证据中尚不明确。
- 描述既往自身免疫性疾病患者使用ICIs的观察性和病例级证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immune checkpoint inhibitors (ICIs) are improving prognoses in advanced stage cancers, but they also lead to immune-related adverse events (IRAEs). IRAEs targeting many organ systems have been reported, but musculoskeletal and rheumatic IRAEs have not been well-characterized. We systematically reviewed published literature on musculoskeletal and rheumatic IRAEs to better understand prevalence and clinical characteristics. METHODS: Medline and CENTRAL databases were searched for articles reporting rheumatic and musculoskeletal IRAEs secondary to ICI treatment. After screening abstracts and full texts in duplicate, clinical features, prevalence, and treatment data were extracted and summarized. RESULTS: A total of 1,725 unique abstracts were screened; 231 contained original data and were about ICIs and went to full-text screening. Fifty-two of these contained information about musculoskeletal or rheumatic IRAEs or about treatment with ICIs in preexisting autoimmune disease. Of these, 33 were clinical trials, 3 were observational studies, and 16 were case reports or series. Arthralgia prevalence in clinical trials ranged 1-43%, and myalgia was reported in 2-20%. Arthritis was reported in 5 of 33 clinical trials, and vasculitis was reported in only 2. One observational study and 3 case reports described patients with preexisting autoimmune disease treated with ICIs. Case reports included development of inflammatory arthritis, vasculitis, myositis, and lupus nephritis. CONCLUSION: Arthralgia and myalgia have been reported commonly in patients treated with ICIs. The prevalence of rheumatic IRAEs such as inflammatory arthritis, vasculitis, and sicca syndrome is less clear from current evidence. There is limited observational and case-level evidence describing ICI use in patients with preexisting autoimmune disease.
引用
- Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. Arthritis Care Res (Hoboken). 2017. PMID: 27998041. doi:10.1002/acr.23177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。